Open AccessCompugen, Ltd
Author(s) -
Eli Zangvil
Publication year - 2007
Publication title -
pharmacogenomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.541
H-Index - 91
eISSN - 1744-8042
pISSN - 1462-2416
DOI - 10.2217/14622416.8.10.1461
Subject(s) - milestone , commercialization , drug discovery , new product development , companion diagnostic , product (mathematics) , business , engineering ethics , data science , computer science , engineering , medicine , bioinformatics , cancer , marketing , biology , geometry , mathematics , archaeology , history
Compugen’s mission is to be the world leader in the discovery and licensing of product candidates to the drug and diagnostic industry. The Company’s powerful discovery engines enable the predictive discovery of numerous potential therapeutics and diagnostic biomarkers. This capability results from the Company’s decade-long pioneering efforts in the deeper understanding of important biological phenomena at the molecular level through the incorporation of ideas and methods from mathematics, computer science and physics into biology, chemistry and medicine. To date, Compugen’s product discovery efforts and its initial discovery engines have focused mainly on the areas of cancer, immune-related and cardiovascular diseases. The Company’s primary commercialization pathway for its product candidates is to enter into milestone and revenue sharing out-licensing and joint development agreements with leading therapeutic and diagnostic companies.